Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3689f is a short (20-24 nucleotide) non-coding RNA molecule that functions in post-transcriptional regulation of gene expression in multicellular organisms. It is produced through a multi-step biogenesis process, starting as a primary transcript cleaved by the Drosha enzyme, then processed into a precursor miRNA, and finally by Dicer into a mature microRNA. The mature form is incorporated into the RNA-induced silencing complex (RISC), which recognizes and binds target mRNAs via imperfect base pairing, typically resulting in translational inhibition or destabilization of the target mRNA. MIR3689F is linked to diseases such as lip cancer but is not a typical therapeutic target like receptors, enzymes, or transporters. MicroRNAs, including MIR3689F, do not encode for proteins but instead regulate gene expression by affecting mRNA stability and translation. While miRNAs are increasingly significant in disease research and may serve as biomarkers or functional effectors, there is no evidence that MIR3689F is directly targeted by drugs or widely used as a therapeutic target in drug development at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3689f (MIR3689F).